Thyrocare Technologies Ltd IPO Message Board (Page 83)

Any idea about price band of thyrucare and ujn.

i think thycore may get subscribe 4 5 times

TTL and ufl 2 no me kon sha IPO best hai....?????

I think,
both are sexy(Dipikaben and Katrina),
ufl is much sexy than TTL.

EHL
Large no. of shares allocated to retail category. Large no. of retail portion will come for sell on listing day.
I suggest if you have holding capacity then wait for some time 3 to 4 weeks. See the ipo launch and listing of Ujjivan.
I observed in many ipos , if new ipo is launched then some momentum shown in it''''''''s peers which is already listed. Like sks micro, SpiceJet etc.

on which date price band will announce ?

septa sir what is technique to analyse fertiliser shares ?

Septaji.natural gas price is very importent for fertilizer sector

Arup u right however that is universal

ok sir

septa sir i think ujjivan fina fair value 246 whats your calculation ?

i have not yet read DRHP once i read i will comment

TTL or UFL priceband kab decleir hoga ?

since the issue will open one 27th we will come to know before 21st April 4 business day from issue date it should be out by then

Two different price band and total issue have been doing round which are as follows:
1. 430-445 price band issue size 480 Cr this value the company at 40 PE with MC of 2400
2. 565-595 price band issue size 640 Cr this value the company at 50 PE MC 3200


at 445 price band this one best issue to come no question just pt one single lot and if good luck u will get allotment
at 595 price band the issue is pricy however compare to Dr lal which double in size has market cap of 8500 Cr so still can see some list gain.

let see in few days will come to know the price band

I am of the opinion it will come at 445 price band and will be bumper issue all should apply SINGLE LOT ONLY

I am certain that it will be 480 cr issue with 445 pricing...based on some very reliable sources!!!

Anyone can suggest for 15 - 20 stocks to invest long term 3 - 5 years.

Also advise to buy at CMP or in deeps....

1. Apply 10 ipos, you will get at least 5/10, so 5 is over.

2. Consult top boarders for the rest 10-15 stocks.

2. Always buy in dips and average.

septa sir if ronw , roce and cagr above 20 % then stock is good or how to analyse it for different sectors ?

Sorry this post should be in 86, request to Manipo

Vodafone India may raise $2 billion using IPO route

Bharti Airtel
Vodafone India''s stated plan to sell its shares could involve raising of funds to the tune of $2 billion (Rs. 13,300 crore), reported the Mint, citing four sources familiar with the development. The stock offering will potentially be done through the Initial Public Offering (IPO) route by the end of this month or early next month.

Media reports had said on April 8 the parent company Vodafone Group Plc was laying the groundwork for India''s largest IPO. However, the firm then had disclosed that the stock offering would be a pure stake sale by the parent firm or involve primary capital raising.

India''s second-largest telecommunication company in terms of subscriber base, one of the four sources added, has already asked merchant bankers to submit proposals for the IPO mandate this week. By next week it is expected to shortlist investment bankers to pitch for the final IPO mandate.

In reply to an email enquiry, Vodafone India told Mint: "We have previously said we have started preparations for a potential IPO, which includes private conversations with banks." It added: "But this is a lengthy process and no decision will be made until we are at the end of it."

As all the major domestic and international bankers vie for the IPO, another source confirmed that the telco expects to raise up to $2 billion through this process.

Bloomberg reported that the share sale would provide Vodafone funds to expand in India. The country''s rising wages have helped the company''s growth in India outpace it in mature Western markets such as the U.K. The news agency, citing sources, added that London-hedquartered Vodafone may sell 10 percent of its India business, and set the valuation of its operations at $20 billion.

Bharti Airtel, India''s largest telco by number of subscribers, has a market capitalisation of nearly $21.3 billion (Rs.1.4 lakh crore). Idea Cellular, another thriving teleco, has about $6.2 billion (Rs. 41,315.85 crore) in market cap.

Yes. I am really interested. Will be very greatful, if you kindly guide me. Thanks in advance.

@manipo, @maruthi.. To work in SME, I would like to suggest u broker, SMC Global.. They allow to work in SME, u can put order, and if volume, then trade also execute.. Also, u can trade it online, browser base Or Mobile/Tablet Trading Platform which is really best, as it''s developer is Financial Technologies.. You can select this broker...

PNB housing which is also planning an IPO has revised it price on advice of merchant bank which is good news for retail investor.

kostak of Jodi @ 2300 in bhavnagar

kitne dino k baad investor making money so if some one don''t want to apply sell in kostak
but do not post that i am not applying

samaj ne wale samaj gaye hai na samje wo .....

kya kehte ho septaji & eagleye Hai na

eagleye what are gmp of ujjivan and equitas ?

likely dates ?? Link in registrar hai , ipo mei dum hai .

is it 27th April . great !!! jai ho .

In an unusual turn of events, L&T Infotech Ltd on Monday withdrew the draft red herring prospectus (DRHP) it filed with the Securities and Exchange Board of India, and filed it afresh on Tuesday. According to investment bankers, this was necessary becathe estimated size of the issue has been cut by more than 10%. As it turns out, the estimated size of the issue has been cut by almost 30% to around $200 million, according to news reports.

The Nifty IT index has corrected by around 5% since the time L&T Infotech filed its DRHP the first time in end-September.

Clearly, its valuation estimates were far too high to begin with, necessitating the sharp cut in the issue size.

Parent Larsen and Toubro Ltd (L&T), which currently owns all of the company’s shares, is offering a part of its stake in the issue. The number of shares to be issued will remain the same at 17.5 million. Based on the earlier rumoured issue size of up to Rs.2,000 crore, L&T was expecting a valuation of around 24 times fiscal year 2015 earnings. This has been toned down to around 16-17 times.

Large-sized IT services companies such as Tata Consultancy Services Ltd and Infosys Ltd trade well above 20 times FY15 earnings, and so is the case with some smaller-sized firms such as Mindtree Ltd and Hexaware Technologies Ltd. But these firms have grown at faster rates.

Mindtree has grown revenues at an annual average growth rate of 23% in the three years till FY15, while growth at Hexaware has stood at 21.2%. L&T Infotech’s growth was lower at 16.1% during the same period.

Operating profit margins are comparable with Mindtree at around 20%, although they are ahead of Hexaware. However, free cash flow generation is lower at L&T Infotech at around 9% of revenue. For the other two firms, free cash flow generation as a proportion of revenue was in double-digits.

Besides, like most other mid-sized firms, L&T Infotech carries greater risks such as high client concentration. Its two largest customers, Citibank and Chevron, account for 21% of revenue.

Against this backdrop, L&T was clearly aiming too high by demanding valuations of around 24 times trailing earnings earlier. The fact that it has toned down expectations sharply should help the issue sail through.

i think SEBI ALWAYS ISSUE LOSE MAKING IPO AFTER GOOD IPO SO PRICE BAND WILL BE RS 6O0 TO HURT RETAILERS

I compared financials of Throcare and Dr. Lal:
- I don''t think Throcare will give returns like Dr. Lal.
- Dr. Lal is almost 3.5 times bigger in revenue
- Dr. Lal''s profit margin is consistent since last 5 years and comes to 12 to 14 percent
- Throcare''s profit margin coming in the range of 25 to 40 percent
- Lal''s profit margin is very less compared to Throcare
both in the same line and difference between margin is 2 to 3 times
- Throcare''s profit margin is decreases from 40 percent in 2013, 29 percent in 2014 and 25 percent in 2015
- Dr. Lal''s profit margin is consistent from year 2011 to 2015.
- Revenue of throcRe is not increasing compared to Lal.

I am waiting for price band for detail analysis. If it comes with comparable price band then listing gain should be sure but in midterm , return like Dr. LAL is questionable.

very well put Uchit Patel like always price band of 445 to be a run away success however at 595 will be risky bet however even with such high valuation market would lap given this vertical of health care is liked and success of Dr LAL

also market grey premium of 150 Plus is based on price band of 445 if the issue comes at 595 then all this GMP will disappear or reduce to 10 and twenty making this issue un attractive